Catechol-O-methyltransferase (COMT) inhibition is an important advance in t
he treatment of parkinson's disease. This consensus statement provides guid
elines for the optimal use of the only currently available COMT inhibitor,
entacapone (Comtess(R) Orion Pharma (UK) Ltd, Newbury, Berkshire).